Olema: ‘Strong Buy’ Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal

Get the latest on Olema Pharmaceuticals (OLMA): Strong Buy rating, promising breast cancer drug trials, and key catalysts ahead.